Potential savings of harmonising hospital and community formularies for chronic disease medications initiated in hospital

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Lapointe Shaw, Lauren ^a   Fischer, Hadas D ^b   Newman, Alice ^b   John Baptiste, Ava ^c   Anderson, Geoffrey M ^b,c,d   Rochon, Paula A ^a,b,c,d   Bell, Chaim M ^a,b,d,e  

^a UNIVERSITY OF TORONTO   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CHRONIC DISEASE; COMMUNITY CARE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG FORMULARY; FEMALE; FUNDING; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT IDENTIFICATION; PRESCRIPTION;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC DISEASE; COST SAVINGS; FEMALE; FORMULARIES AS TOPIC; FORMULARIES, HOSPITAL; HUMANS; MALE;

EID: 84862729993     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039737     Document Type: Article

References (41)

1. Canadian Institute for Health Information Research Institute (2010) Healthcare in Canada 2010. Ottawa (ON): CIHI. Available:http://secure.cihi.ca/cihiweb/products/HCIC_2010_Web_e.pdf. Accessed 2012 February 18.
2. Ministry of Health and Long-Term Care. 2007/2008 Interim Report Card for the Ontario Drug Benefit Program. Available:http://www.health.gov.on.ca/english/providers/pub/pub_menus/pub_drugs.html. Accessed 2011 June 16.
3. Jackevicius CA, Cox JL, Carreon D, Tu JV, Rinfret S, et al. (2009) Long-term trends in use of and expenditures for cardiovascular medications in Canada. CMAJ 181(1-2): E19-28.
4. Menon D, (2001) Pharmaceutical Cost Control In Canada: Does It Work? Health Affairs 20(3): 92-103.
5. Morgan SG, Barer ML, Agnew JD, (2002) Whither Seniors' Pharmacare: Lessons From (And For) Canada. Health Affairs 22(3): 49-59.
6. Howlett K, (2010) Provinces to team up on drug purchases. The Globe and Mail. Available:http://pharmacarenow.ca/provinces-to-team-up-on-drug-purchases. Accessed 2011 June 17.
7. Boockvar K, Fishman E, Kyriacou CK, Monias A, Gavi S, et al. (2004) Adverse events due to discontinuations in drug use and dose changes in patients transferred between acute and long-term care facilities. Arch Intern Med 164(5): 545-550.
8. Bell CM, Fischer HD, Gill SS, Zagorski B, Sykora K, et al. (2007) Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med 22(7): 1024-1029.
9. Bell CM, Bajcar J, Bierman AS, Li P, Mamdani MM, et al. (2006) Potentially unintended discontinuation of long-term medication use after elective surgical procedures. Arch Intern Med 166(22): 2525-2531.
10. Bell CM, Brener SS, Gunraj N, Huo C, Bierman A, et al. (2011) Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 306(8): 840-847.
11. Richardson SP, Cooper W, Cole C, (1991) The power of group purchasing. Dimens Health Serv 68(7): 17-18.
12. Anon. Medbuy. Available:http://www.medbuy.ca/en/Default.aspx. Accessed 2001 July 4.
13. Anon. HealthPRO. Available:http://www.healthprocanada.com/. Accessed 2011 July 4.
14. Williams JI, Young W, (1996) A summary of studies on the quality of health care administrative databases in Canada. In: Patterns of Health Care in Ontario. The ICES Practice Atlas. Ottawa (ON): Canadian Medical Association. pp. 339-45.
15. Levy AR, O'Brien BJ, Sellors C, Grootendorst P, Willison D, (2003) Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol 10(2): 67-71.
16. Public Health Agency of Canada (2005) Leading Causes of Death and Hospitalisation in Canada. Ottawa (ON).: Public Health Agency of Canada. Available:http://www.phac-aspc.gc.ca/publicat/lcd-pcd97/table2-eng.php. Accessed 2011 July 9.
17. Armstrong D, Marshall JK, Chiba N, Enns R, Falone C, et al. (2005) Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults- update 2004. Can J Gastroenterol 19(1): 15-35.
18. Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, et al. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113(19): 2363-2372.
19. Lambert M, (2011) AHA/ASA Guidelines on Prevention of Recurrent Stroke. Am Fam Physician 83(8): 993-1001.
20. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Darmuth C, et al. (2002) Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ 166(6): 737-745.
21. Bell CM, Telio D, Goldberg AFG, Margulies A, Booth GL, (2007) Selective Therapeutic Interchange Practices in Ontario Acute Care Hospitals. Hospital Pharmacy 60(5): 315-318.
22. Ministry of Health and Long-Term Care. Ontario Drug Benefit: The Program. Available:http://www.health.gov.on.ca/english/public/pub/drugs/odb.html. Accessed 2012 April 16.
23. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, et al. (2009) Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9): 937-944.
24. Angiolillo DJ, Gibson CM, Cheng S, Ollier C, Nicolas O, et al. (2001) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89(1): 65-74.
25. Gilard M, Arnaud B, Cornily J-C, Le Gal G, Lacut K, et al. (2008) Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 51(3): 256-260.
26. Furuta T, Iwaki T, Umemura K, (2010) Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol 70(3): 383-392.
27. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, et al. (2005) Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 43(11): 1130-1139.
28. Ministry of Health and Long-Term Care. Formulary Downloads: Edition 41. Available:http://www.health.gov.on.ca/english/providers/program/drugs/edition_41.html. Accessed 2012 February 18.
29. World Health Organization. Defined Daily Dose (DDD) Index. Available:http://www.whocc.no/atc_ddd_index/. Accessed 2011 June 17.
30. Levine S, Campen D, Millares M, Barrueta A, (2000) Kaiser Permanente's Prescription Drug Benefit. Health Affairs 19(2): 185-190.
31. Tordoff JM, Norris PT, Reith DM, (2008) "Price Management" and Its Impact on Hospital Pharmaceutical Expenditure and the Availability of Medicines in New Zealand Hospitals. Value in Health 11(7): 1214-1226.
32. Pilote L, Abrahamowicz M, Rodrigues E, Eisenberg MJ, Rahme E, et al. (2004) Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med 141(2): 102-112.
33. Guyatt Gordon, (2001) Don't allow drug firms to intimidate. Hamilton Spectator and Straight Goods. Available:http://www.medicalreformgroup.ca/drug.firms.intimidate.pdf. Accessed 2012 February 18.
34. John C Ballin, (1987) Therapeutic Substitution-Usurpation of the Physician's Prerogative. JAMA 257(4): 528-529.
35. Schneeweiss S, Maclure M, Dormuth C, Avorn J, (2002) Pharmaceutical cost containment with reference-based pricing: time for refinements. CMAJ 167(11): 1250-1251.
36. Aaserud M, Dahlgren AT, Kösters JP, Oxman AD, Ramsay C, et al. (2006) Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst Rev (2): CD005979.
37. Morgan S Kozyrskyj A, Metge C, Roos N, Dahl M, (2003) Pharmaceuticals: Therapeutic Interchange and Pricing Policies. Winnipeg (Manitoba): Manitoba Centre for Health Policy, Dept. of Community Health Sciences, Faculty of Medicine, University of Manitoba. 47 p.
38. Ministry of Health and Long-Term Care. Legislation- Drug System Reforms. Available:http://www.health.gov.on.ca/en/public/programs/drugreforms/legislation.aspx. Accessed 2011 June 17.
39. Bell C, Griller D, Lawson J, Lovren D, (2010) Generic drug pricing and access in Canada: What are the implications? Toronto (ON): Health Council of Canada. Available:http://www.secorgroup.com/files//pdf/ARTICLES/generics_June182010_rpt.pdf. Accessed 2012 February 18.
40. Jackevicius CA, Li P, Tu JV, (2008) Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 117(8): 1028-1036.
41. Anon. HealthPRO Terms and Conditions. Available:http://www.healthprocanada.com/Terms_Conditions.gk. Accessed 2011 November 6.